Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Hematology Am Soc Hematol Educ Program. 2015;2015:649-51. doi: 10.1182/asheducation-2015.1.649.

Abstract

A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DIPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.

MeSH terms

  • Aged
  • Disease Progression
  • Enzyme Inhibitors / therapeutic use
  • Hematology / methods*
  • Hematology / standards
  • Humans
  • Janus Kinases / antagonists & inhibitors*
  • Male
  • Myeloproliferative Disorders / drug therapy*
  • Polycythemia Vera / drug therapy*
  • Primary Myelofibrosis / drug therapy*
  • Pyrazoles / therapeutic use
  • Risk

Substances

  • Enzyme Inhibitors
  • INCB018424
  • Pyrazoles
  • Janus Kinases